Sign Out
Pharmacology: Mechanism of Action: Trimetazidine hydrochloride (ANGIREL MR) inhibits beta oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase. which enhances glucose oxidation. In ischemic cell. energy obtained during glucose oxidation requires less oxygen consumption than in the beta oxidation process. Potentiation of glucose oxidation optimizes cellular energy processes, thereby maintaining proper energy metabolism during ischemia.
Pharmacodynamic effects: In patients with ischemic heart disease, Trimetazidine hydrochloride (ANGIREL MR) acts as a metabolic agent, preserving myocardial high-energy phosphate intracellular levels. Anti-ischemic effects are achieved without concomitant hemodynamic effects.
Clinical efficacy and safety: Clinical studies have demonstrated the efficacy and safety of Trimetazidine hydrochloride (ANGIREL MR) in the treatment of patients with chronic angina, either alone or when the benefit from the other antianginal medicinal products was insufficient.
